Issues

Home > Issues (Page 20)

August 19, 2020 Briefs, Price and Costs

SAN FRANCISCO – California’s surprise medical billing law (Assembly Bill 72) – which imposes price controls on the rates out-of-network physicians can charge at in-network facilities – is hurting patients with lower quality care, reduced access, and higher health care system costs, finds a new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the brief “California’s surprise medical billing law has created unintended consequences that are increasing healthcare costs and...

August 18, 2020 Coronavirus

PRI's Dr. Wayne Winegarden joins the Pegasus Institute to discuss the danger of price controls in health care including hurting rural health care providers and threatening the already thin margins many hospitals operate on. Winegarden also talks about the impact of the coronavirus and COVID-19. Pegasus Institute · The Problem With Price Controls in Healthcare with Wayne Winegarden of Pacific Research Institute...

August 17, 2020 Coronavirus

Last August, Chris Walcroft, a 50-year old Canadian father of two, was told that he would be dead within a year without dialysis, according to reporting from CTV News. His kidneys were failing. His doctor scheduled a surgery for mid-March to implant a fistula, which is necessary for dialysis. Modern medical technology would afford Walcroft a chance to see his kids graduate from high school. Then the pandemic came. The Canadian government mandated across-the-board delays of "elective" surgeries to shore up personnel...

August 16, 2020 Coronavirus

Here’s a thought experiment: after the RMS Titanic collided with an iceberg, it became necessary to allocate seats on the lifeboats; there were only about 700 places for the 2208 passengers. What if seats had been auctioned, with the price determined by supply and demand—i.e., by market forces? Clearly, the wealthiest would have crowded out the others. Instead, the Captain decided that women and children should take precedence. Of course, children had the most life to lose, but why women...

August 14, 2020 Coronavirus

The value of innovative medicines has absolutely nothing to do with its cost of production. Yet, not only does this myth persist, it appears to be growing. In the latest example, an article in the Journal of Virus Eradication claims that drugs being repurposed in the hopes they might be effective treatments for Covid-19, such as remdesivir and sofosbuvir, could be profitable at very low costs. How do the authors come up with this conclusion? They claim that the costs of production range between...

August 12, 2020 Coronavirus

here is widespread anticipation of publicly available vaccines to prevent COVID-19 infections, so that we can “get back to normal.” Some three dozen, made with a variety of technology platforms, are in clinical trials. Several of the more promising vaccine development programs have been assisted by a White House crash program, “Operation Warp Speed,” which was launched in May. At the announcement, President Donald Trump said the goal would be to have 300 million doses of a vaccine available by the end of this year. Unfortunately, but inevitably,...

August 12, 2020 Coronavirus

Dr. Henry Miller joins the nationally-syndicated Lars Larson Show to get an update on everything COVID-19. Miller and Larson discuss the status of Operation Warp Speed, the Trump Administration's initiative to develop a coronavirus vaccine. Miller explains that the FDA said they will be very transparent as data and testing becomes finalized and he thinks there is reason to be optimistic about rapid development of a virus that is thoroughly reviewed. Miller also talks about the lack of data in international...

August 12, 2020 Infographics, Multimedia, Price and Costs

The Professor and Pete must collect 3 keys to finally escape the drug pricing maze.  The first key involves reforms to increase drug affordability for patients who buy their drugs at a pharmacy.  The Professor shows Pete that these reforms should ensure that prices are transparent, easy to understand, and help patients benefit from the large discounts that are being paid....

August 10, 2020 Coronavirus

Last week, National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci urged states with rising COVID-19 rates to consider a new round of lockdown restrictions. "You may need to pause, you may need to drop back a little bit," Fauci said. "I don't think you necessarily have to revert to go all the way back to reclosing." As they try to get the coronavirus' spread under control, states must resist the urge to impose blanket stay-at-home orders. Such draconian measures can cause people to postpone important medical care...

August 5, 2020 Coronavirus

By: Henry I. Miller, M.S., M.D., Kathleen L. Hefferon, Justin R. St. Juliana Like most institutions in American society, academia has been badly shaken by Covid-19. Many universities in the Northeast abruptly closed as the pandemic accelerated. Students were sent home, which in some cases involved returning to the other side of the globe. Faculty and staff at many institutions were offered emergency training workshops on everything from supporting student mental health to how to use video-conferencing platforms. Even before the pandemic,...

August 3, 2020 Coronavirus

As Americans eagerly anticipate a COVID-19 vaccine, there's troubling new evidence that they're failing to get inoculated against other infectious diseases. To get vaccination rates back where they need to be, policymakers must remind the public of the importance of routine immunizations and remove the regulatory barriers that make it difficult for people to get their shots. A recent study of patients in Michigan found a significant reduction in vaccinations among all age groups. As of late May, fewer than half of...

July 31, 2020 Issues, Price and Costs

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text css=".vc_custom_1596236774320{padding-right: 40px !important;}"]DOWNLOAD THE PDF In October 2019, the Center for Medical Economics and Innovation at the Pacific Research Institute, under the direction of Dr. Wayne Winegarden, released its second study documenting the savings potential enabled by biosimilars. Biosimilars are medicines manufactured in, or derived from, biological sources that are developed to be similar to FDA-approved reference products. Biosimilars are only approved to compete in nine biologic drug classes in the U.S.,...

July 31, 2020 Coronavirus

There is widespread anticipation of vaccines to prevent COVID-19 infections so life can “get back to normal.” Some three dozen vaccines, made with a variety of technology platforms, or approaches (naked RNA, weakened or killed viruses, hybrid viruses, subunit vaccines, etc.), are now in clinical trials. Many of these vaccine development programs have been assisted by a White House crash program, “Operation Warp Speed,” which was launched in May. At the announcement, President Trump said the goal would be to have 300 million doses of a...

July 30, 2020 Coronavirus

Title: Trump's proposed executive orders on drug pricing may hinder R&D and drug development Jeff Lagasse, Associate Editor, Health Care Finance Recently, President Trump proposed four different executive orders aimed at lowering drug prices in a move that some see as calculated to secure votes from seniors in the run-up to November's presidential election. There's no doubt that drug prices have become a challenge for many Americans, but as finer details of the executive orders have yet to emerge, it's unclear whether...

July 29, 2020 Issues, Policy Proposals

Millions of people will continue to have access to affordable short-term health plans, thanks to a new ruling from the U.S. District Court of Appeals for the District of Columbia. A three-judge panel of the court upheld by a 2-1 margin a Trump administration rule extending the maximum duration of a short-term plan to just under a year. Insurers can also renew the plans for up to three years. Short-term plans are appealing because they're so affordable. Unlike those for sale on the exchanges, they're not required to...

July 28, 2020 Coronavirus-Alternate2, Innovation, Issues

It's hard to find a silver lining in a pandemic. But one of the few may be the rapid rise of telemedicine. With people stuck at home, doctors retooled their practices to see patients via videoconference. Insurance companies and regulators expanded the number of services available via telemedicine—and made reimbursement for telehealth consultations on par with conventional in-person visits. The Federal Trade Commission has now called on officials at the Centers for Medicare & Medicaid Services (CMS)  to permanently extend the emergency...

July 27, 2020 Coronavirus - Alternate, Issues

By Shiv Sharma and Henry I. Miller, M.S., M.D. As the nation emerges in fits and starts from the lockdowns spurred by the first wave of COVID-19 illnesses, we're beginning to appreciate the full impact of the pandemic, how tenacious it is, and that the sickness and death directly caused by the virus are only part of the picture. The three-month-plus suspension of routine, non-emergency medical care has created secondary, silent epidemics of societal and medical problems that require the urgent focus...

July 24, 2020 Issues, Policy Proposals

Sally C. Pipes joins the Lars Larson Show to question the Trump administration's latest action on drug pricing. President Trump plans to sign an executive order on Friday, July 24 that puts limits on drug pricing in the United States. Pipes explains that 90 percent of drugs are generic and already save most Americans a great deal of money. But the pending executive order ties the average reference drug price to those in other countries - Canada, UK, Germany, France,...

July 24, 2020 Issues, Policy Proposals

President Trump issued four executive orders Friday that he said will lower drug prices — but in reality, three of the orders will cause far more harm than good and represent electioneering at its worst. The three harmful executive orders allow the importation of drugs from Canada, reduce the price of insulin, and introduce an International Pricing Index for prescription drugs. The International Pricing Index will effectively impose price controls on prescription drugs under Medicare Part B — and in so doing, dramatically...